Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 2
2012 1
2013 3
2014 4
2017 1
2018 1
2020 1
2021 1
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Finn RS, et al. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. N Engl J Med. 2020. PMID: 32402160 Clinical Trial.
Targeting Mutated KRAS Genes to Treat Solid Tumours.
Krishnan T, Roberts-Thomson R, Broadbridge V, Price T. Krishnan T, et al. Among authors: broadbridge v. Mol Diagn Ther. 2022 Jan;26(1):39-49. doi: 10.1007/s40291-021-00564-0. Epub 2021 Dec 16. Mol Diagn Ther. 2022. PMID: 34914038 Review.
Cetuximab in metastatic colorectal cancer.
Broadbridge VT, Karapetis CS, Price TJ. Broadbridge VT, et al. Expert Rev Anticancer Ther. 2012 May;12(5):555-65. doi: 10.1586/era.12.25. Expert Rev Anticancer Ther. 2012. PMID: 22594891 Review.
Reversing Hyperammonemia in Neuroendocrine Tumors.
Broadbridge V, Townsend A, Pittman K, Kimber R, Patterson W, Sukumaran S, Price TJ. Broadbridge V, et al. J Clin Gastroenterol. 2010 Sep;44(8):e186-9. doi: 10.1097/MCG.0b013e3181d96aad. J Clin Gastroenterol. 2010. PMID: 20453660
Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study.
Dean A, Gill S, McGregor M, Broadbridge V, Järveläinen HA, Price T. Dean A, et al. Among authors: broadbridge v. Lancet Gastroenterol Hepatol. 2022 Oct;7(10):943-951. doi: 10.1016/S2468-1253(22)00167-4. Epub 2022 Jul 6. Lancet Gastroenterol Hepatol. 2022. PMID: 35803294 Clinical Trial.
Contrast induced hyperthyroidism due to iodine excess.
Mushtaq U, Price T, Laddipeerla N, Townsend A, Broadbridge V. Mushtaq U, et al. Among authors: broadbridge v. BMJ Case Rep. 2009;2009:bcr06.2009.1982. doi: 10.1136/bcr.06.2009.1982. Epub 2009 Nov 4. BMJ Case Rep. 2009. PMID: 22053166 Free PMC article.
Can we accurately report PTEN status in advanced colorectal cancer?
Hocking C, Hardingham JE, Broadbridge V, Wrin J, Townsend AR, Tebbutt N, Cooper J, Ruszkiewicz A, Lee C, Price TJ. Hocking C, et al. Among authors: broadbridge v. BMC Cancer. 2014 Feb 25;14:128. doi: 10.1186/1471-2407-14-128. BMC Cancer. 2014. PMID: 24564252 Free PMC article. Clinical Trial.
17 results